spacer
home > ict > autumn 2009 > database dynamics
PUBLICATIONS
International Clinical Trials

Database Dynamics

 

The pharmaceutical industry today faces a perfect storm of events that are challenging its ability to bring new drugs to market. Drug companies are seeing fewer new drugs entering the market worldwide, R&D productivity is slipping, clinical trials costs are escalating, and senior drug development executives are seeking new strategies to increase the number of successfully completed clinical trials. For many pharmaceutical companies, CROs are an important part of their drug development efforts. They represent an essential, and growing, force in the effort to develop new products efficiently and economically. A recent survey of pharmaceutical professionals involved in CRO outsourcing and project management demonstrates the importance of implementation detail in the selection of a CRO when they conduct one or more studies for a sponsor company. This article demonstrates how a CRO can use clinical grants to illustrate this implementation detail during both the project selection and project conduct portions of clinical studies.

Today, CRO use is on the rise. In survey after survey, pharmaceutical company and CRO respondents say that they expect to see more outsourcing (1). Moreover, many companies think CROs provide great flexibility. They can be used in a wide variety of ways, from a preferred provider with responsibility for conducting almost all of a company’s clinical trial activity, to just one of many CROs bidding to conduct a portion of one clinical trial. Whichever way sponsor companies choose to use CROs, most clinical development professionals expect their use to expand greatly in the years ahead.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Currently serving in the role of Clinical Site Agreements Consultant for PAREXEL International, LLC, Keitia Brooks has been in contracts management for over 10 years within the private and public sectors, which includes the healthcare and government industries. Keitia’s primary focus is the development of the CRO’s global investigator grant estimates for their clients and sponsors.

Jeanelle Pierre is a Senior Client Manager at TTC, llc, which provides clinical trial benchmark information to the pharmaceutical industry. In this position Jeanelle’s knowledge of international outsourcing and clinical development continues to guide the product and its utilisation among industry leaders. With her BSc in Computer Programming she has been able to provide guidance in system development, including management of TTC’s latest benchmarking tool for IITs.

spacer
Keitia Brooks
spacer
spacer
spacer
Jeanelle Pierre
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI post-pandemic executive pharma survey: COVID-19 driving manufacturing and CDMOs driving growth

Amsterdam, 22nd April 2021: Ahead of CPhI Discover (17th-28th May, 2021) – global pharma’s largest ever virtual gathering – the CPhI executive post-pandemic pharma survey predicts that pandemic supply chain issues have further cemented a push for repatriated manufacturing globally. The findings suggest that over the next five years, governments and companies will gradually look to reduce complexity and increase regional self-reliance.
More info >>

White Papers

Another Successful Visit Against the Odds

Medical Research Network (MRN) Limited

Our dedicated team of nurses, couriers and project managers deliver, come rain or shine. Making sure a Clinical Trial visit can go ahead in the home can be a complex process, and last month bad weather nearly stopped play on an important Home Trial Support visit. Thanks to the commitment and dedication from the entire team it went ahead against the odds.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement